Adial Pharmaceuticals Inc... (ADIL)
0.70
-0.00 (-0.01%)
At close: Apr 24, 2025, 3:07 PM
0.68
-3.46%
After-hours: Apr 24, 2025, 07:44 PM EDT
-0.01% (1D)
| Bid | 0.62 |
| Market Cap | 4.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.2M |
| EPS (ttm) | -2.72 |
| PE Ratio (ttm) | -0.26 |
| Forward PE | -0.52 |
| Analyst | Buy |
| Ask | 0.73 |
| Volume | 8,693 |
| Avg. Volume (20D) | 813,418 |
| Open | 0.74 |
| Previous Close | 0.70 |
| Day's Range | 0.70 - 0.74 |
| 52-Week Range | 0.58 - 3.00 |
| Beta | 1.26 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2018
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ADIL
Website https://www.adialpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 1034.75% from the latest price.
Stock Forecasts1 month ago
+20.64%
Adial Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
+15.04%
Adial Pharmaceuticals shares are trading higher after the company announced results from its AD04-103 pharmacokinetics study for AD04, aimed at treating alcohol use disorder.
